Cite
HARVARD Citation
Hong, D. et al. (n.d.). First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET. European journal of cancer. pp. S1-. [Online].